Affinity Asset Advisors LLC Sells 47,390 Shares of NewAmsterdam Pharma (NASDAQ:NAMS)

Affinity Asset Advisors LLC lessened its position in shares of NewAmsterdam Pharma (NASDAQ:NAMS) by 10.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 425,000 shares of the company’s stock after selling 47,390 shares during the period. NewAmsterdam Pharma makes up about 1.5% of Affinity Asset Advisors LLC’s portfolio, making the stock its 22nd largest holding. Affinity Asset Advisors LLC’s holdings in NewAmsterdam Pharma were worth $10,922,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Geode Capital Management LLC raised its position in NewAmsterdam Pharma by 1.6% during the third quarter. Geode Capital Management LLC now owns 86,322 shares of the company’s stock valued at $1,433,000 after purchasing an additional 1,399 shares in the last quarter. National Bank of Canada FI acquired a new position in NewAmsterdam Pharma during the fourth quarter worth about $51,000. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of NewAmsterdam Pharma in the fourth quarter worth about $80,000. Legal & General Group Plc lifted its holdings in shares of NewAmsterdam Pharma by 24.8% in the fourth quarter. Legal & General Group Plc now owns 22,946 shares of the company’s stock worth $590,000 after acquiring an additional 4,556 shares during the last quarter. Finally, KLP Kapitalforvaltning AS acquired a new stake in shares of NewAmsterdam Pharma in the 4th quarter valued at approximately $154,000. Institutional investors and hedge funds own 89.89% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on NAMS shares. Royal Bank of Canada reaffirmed an “outperform” rating and set a $40.00 target price on shares of NewAmsterdam Pharma in a research note on Friday, January 24th. HC Wainwright reiterated a “buy” rating and set a $48.00 target price on shares of NewAmsterdam Pharma in a research report on Tuesday, January 14th. UBS Group set a $41.00 price target on shares of NewAmsterdam Pharma in a research report on Monday, March 3rd. Needham & Company LLC reissued a “buy” rating and issued a $42.00 price objective on shares of NewAmsterdam Pharma in a research note on Tuesday, April 8th. Finally, Scotiabank lifted their target price on NewAmsterdam Pharma from $47.00 to $52.00 and gave the stock a “sector outperform” rating in a report on Thursday, February 27th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $43.33.

NewAmsterdam Pharma Stock Up 8.6 %

NewAmsterdam Pharma stock opened at $16.42 on Tuesday. The company has a market capitalization of $1.80 billion, a PE ratio of -6.32 and a beta of -0.01. The firm’s fifty day moving average is $20.17 and its 200 day moving average is $21.30. NewAmsterdam Pharma has a 12-month low of $14.06 and a 12-month high of $27.29.

NewAmsterdam Pharma (NASDAQ:NAMS) last released its quarterly earnings data on Wednesday, February 26th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.47). The firm had revenue of $12.77 million for the quarter, compared to the consensus estimate of $3.30 million. Sell-side analysts expect that NewAmsterdam Pharma will post -1.75 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director James N. Topper bought 1,135 shares of the stock in a transaction dated Wednesday, March 26th. The stock was bought at an average price of $22.49 per share, for a total transaction of $25,526.15. Following the completion of the acquisition, the director now directly owns 3,013,569 shares in the company, valued at approximately $67,775,166.81. This trade represents a 0.04 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CAO Louise Frederika Kooij sold 150,000 shares of the company’s stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $20.37, for a total transaction of $3,055,500.00. Following the sale, the chief accounting officer now directly owns 15,000 shares in the company, valued at approximately $305,550. This trade represents a 90.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 19.50% of the stock is currently owned by company insiders.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.